In the treatment of rheumatic diseases (rheumatoid arthritis, spondylarthritides), chronic inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and psoriasis, TNF-α inhibitors such as adalimumab (ADL; commercial name Humira®) and infliximab (IFX; commercial name Remicade®) are given when patients respond insufficiently to conventional disease-modifying antirheumatic drugs (DMARDs) or these are contraindicated.
Increasing ADL or IFX levels in the treatment lead to continuous improvement of the clinical symptoms. After reaching the optimal concentration range, further increase of the active ingredient no longer significantly improves the symptoms, but may lead to side effects. In order to reach the optimal range, the drug dosage must be adjusted individually.
If the drug level drops significantly, this indicates the production of body-own anti-drug antibodies (ADA), a frequent problem in the treatment with TNF-α inhibitors. These endogenous antibodies complex the drug, which leads to its premature elimination from the body and/or interruption of the effect mechanism. In patients who do not respond to the treatment, ADA occur more frequently and in higher concentrations than in patients who are being successfully treated with ADL and IFX.
The continuous monitoring of the levels of TNF-α inhibitors during the treatment enables individual adjustment of the drug dosage or the injection interval and thus ensures individualised, targeted and cost-effective patient care.
The determination of ADA can facilitate decision making with respect to strategic therapy adjustments. According to the reactive strategy of therapeutic drug monitoring using the Mab-Track ELISA, ADA determination should only take place when the drug level sinks below a defined threshold value.
Licda.Rosa Hernandez & Lic. Oscar Sandoval
INSULAB S.A. de C.V
End of calle padres aguilar and 79 av. sur
Clinica Corazon de Maria, Colonia Escalon
Jose Ricardo Acosta
DIPRODI (Distribuidora de Productos Para DiagnosticoS. De R.L. de C.V.)
ph 22307121 Tegucigalpa
Residencial Palza, Bloque 32, Casa No. 1
Ms. Triana Delfin
Circ. Durango 1429 1C
Phone: +598 2 916 8969
vCard Download vCard
Abdulsamad Allengawi / Adil Muneeb
Global Consultancy House (GCH)
Road No. 18, Block No: 321, Exhibition Avenue
Office: 22, Building No: 232, Mohammed Jalal Building
Kingdom of Bahrain
Mr Stephen Harland-Smith
ESL Biosciences (Australia) (2012) Pty
2150 New South Wales
2-4 Giffnock Avenue
PO Box 202 / Macquarie Park Business Hub /North Ryde BC, NSW 1670, Australia Suite 3
Dr. Khalifa Eltayeb Khalafalla
K-BIOanalytica Co. Ltd.
Al -Sayed Abdel Rahman Street / Al Qasr street Junction
Rayan Specialized laboratory Building/ P.O.Box 11656
Khalid Abdalla Abdelrahim AL Fahim
AL Fahim Health Care Solutions LLC
Boulevard Plaza Tower 2, Office 1904
United Arab Emirates